Foresite Capital Management V, LLC
CIK 1792206 · View on SEC EDGAR ↗
- Portfolio value
- $362.2M
- Positions
- 9
- As of
- June 30, 2026
Portfolio value QoQ: +33.7% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 9
- Effective number of positions
- 3.7
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.25% Est. buys $34,924,133 · sells $782,987
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 69.2% still held
- New positions
- 1
- Increased
- 2
- Decreased
- 1
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +93.8% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 98.8% · Options excluded: 0.0%
Sector breakdown
Full portfolio 9 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| ALMS Alumis Inc. - Common Stock | $165,941,439 | 45.81% | 5,896,995 | $36,030,639 | |||
| CGON CG Oncology, Inc. - Common stock | $76,666,503 | 21.17% | 1,079,050 | $8,712,399 | Up ×1 | ||
| IRON Disc Medicine, Inc. - Common Stock | $27,359,407 | 7.55% | 374,069 | $3,441,435 | |||
| HIMS Hims & Hers Health, Inc. Class A Common Stock | $25,591,695 | 7.07% | 738,151 | $10,267,680 | |||
| PHVS Pharvaris N.V. - Ordinary Shares | $22,966,030 | 6.34% | 664,142 | $17,481,999 | Up ×1 | ||
| EIKN Eikon Therapeutics, Inc. - Common Stock | $17,212,728 | 4.75% | 1,318,983 | $3,257,888 | |||
| Unknown issuer (CUSIP: 67613T104) | $13,342,195 | 3.68% | 713,105 | Up ×1 | |||
| LYEL Lyell Immunopharma, Inc. - Common Stock | $6,693,223 | 1.85% | 476,386 | $-2,876,962 | Down ×1 | ||
| NRIX Nurix Therapeutics, Inc. - Common stock | $6,428,900 | 1.77% | 265,000 | $2,321,400 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 67613T104) | $13,342,195 | 713,105 | 3.68% |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.